“There is no answer yet” to the question whether the Omicron mutation of coronavirus, which is spreading rapidly in the US and Europe, requires a vaccine adapted to it, its director said on Tuesday European Medicines Agency (EMA).
“Let me insist that there is still no answer to the question of whether we will need a custom vaccine, with a different composition, to fight this variant or any other,” she said. Emer Cook during a press conference.
According to the APE BPE, she added that “we need more data regarding the impact of variation on the effectiveness of approved vaccines “and how we should” gather additional evidence “about the effectiveness of current vaccines in preventing severe or milder forms of the disease, as well as hospitalization and death.
Cook emphasized, however, that me five vaccines and six drugs against Covid-19, “we are in a much more stable position than last year”.
“We have a lot at our disposal additional tools“, She added, against the background of the approval by the Commission, yesterday, a fifth vaccine against Covid, that of the American Novavax, after the “green light” given by the EMA.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
